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Abstract
Position emission tomography (PET) is a powerful functional imaging modality with wide uses in fields
such as oncology, cardiology, and neurology. Motivated by imaging datasets from a psoriasis clinical trial
and a cohort of Alzheimer's disease (AD) patients, several interesting methodological challenges were
identified in various steps of quantitative analysis of PET data. In Chapter 1, we consider a classification
scenario of bivariate thresholding of a predictor using an upper and lower cutpoints, as motivated by an
image segmentation problem of the skin. We introduce a generalization of ROC analysis and the concept
of the parameter path in ROC space of a classifier. Using this framework, we define the optimal ROC
(OROC) to identify and assess performance of optimal classifiers, and describe a novel nonparametric
estimation of OROC which simultaneous estimates the parameter path of the optimal classifier. In
simulations, we compare its performance to alternative methods of OROC estimation. In Chapter 2, we
develop a novel method to normalize PET images as an essential preprocessing step for quantitative
analysis. We propose a method based on application of functional data analysis to image intensity
distribution functions, assuming that that individual image density functions are variations from a
template density. By modeling the warping functions using a modified function-on-scalar regression, the
variations in density functions due to nuisance parameters are estimated and subsequently removed for
normalization. Application to our motivating data indicate persistence of residual variations in
standardized image densities. In Chapter 3, we propose a nonlinear mixed effects framework to model
amyloid-beta (Aβ), an important biomarker in AD. We incorporate the hypothesized functional form of Aβ
trajectory by assuming a common trajectory model for all subjects with variations in the location
parameter, and a mixture distribution for the random effects of the location parameter address our
empirical findings that some subjects may not accumulate Aβ. Using a Bayesian hierarchical model,
group differences are specified into the trajectory parameters. We show in simulation studies that the
model closely estimates the true parameters under various scenarios, and accurately estimates group
differences in the age of onset.
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ABSTRACT
NOVEL STATISTICAL METHODOLOGIES IN ANALYSIS OF POSITION EMISSION
TOMOGRAPHY DATA: APPLICATIONS IN SEGMENTATION, NORMALIZATION, AND
TRAJECTORY MODELING
Daniel B. Shin
Russell T. Shinohara
Position emission tomography (PET) is a powerful functional imaging modality with wide uses in
fields such as oncology, cardiology, and neurology. Motivated by imaging datasets from a psoriasis
clinical trial and a cohort of Alzheimer’s disease (AD) patients, several interesting methodological
challenges were identified in various steps of quantitative analysis of PET data. In Chapter 1, we
consider a classification scenario of bivariate thresholding of a predictor using an upper and lower
cutpoints, as motivated by an image segmentation problem of the skin. We introduce a generalization of ROC analysis and the concept of the parameter path in ROC space of a classifier. Using this
framework, we define the optimal ROC (OROC) to identify and assess performance of optimal classifiers, and describe a novel nonparametric estimation of OROC which simultaneous estimates the
parameter path of the optimal classifier. In simulations, we compare its performance to alternative
methods of OROC estimation. In Chapter 2, we develop a novel method to normalize PET images as an essential preprocessing step for quantitative analysis. We propose a method based on
application of functional data analysis to image intensity distribution functions, assuming that that
individual image density functions are variations from a template density. By modeling the warping
functions using a modified function-on-scalar regression, the variations in density functions due to
nuisance parameters are estimated and subsequently removed for normalization. Application to
our motivating data indicate persistence of residual variations in standardized image densities. In
Chapter 3, we propose a nonlinear mixed effects framework to model amyloid-beta (Aβ), an important biomarker in AD. We incorporate the hypothesized functional form of Aβ trajectory by assuming
a common trajectory model for all subjects with variations in the location parameter, and a mixture
distribution for the random effects of the location parameter address our empirical findings that
some subjects may not accumulate Aβ. Using a Bayesian hierarchical model, group differences
are specified into the trajectory parameters. We show in simulation studies that the model closely
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estimates the true parameters under various scenarios, and accurately estimates group differences
in the age of onset.
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CHAPTER 1
I NTRODUCTION
The field of biomedical imaging has transformed in recent decades from simple applications, such
as visualization of broken bones using projection radiographs, to vastly more complex applications,
such as quantification of brain activity using functional magnetic resonance imaging. Advances
in imaging technology has made it possible to observe real-time in vivo disease processes, e.g.
the level of impaired bone mineralization or the amyloid plaque burden in the brains of Alzheimer’s
disease (AD) patients, that until recently could only be seen post mortem or using invasive methods
such as biopsies. The transition from qualitative to quantitative applications in biomedical imaging,
along with increasing understanding of the relationship between various disease biomarkers and
clinical outcomes, has highlighted the importance of robust statistical methods.
This dissertation focuses on positron emission tomography (PET) and statistical methodologies inspired by problems encountered during the analysis of PET data. The motivation comes from the
Vascular Inflammation in Psoriasis (VIP) trial. The VIP trial is a multicenter, randomized controlled
trial to assess the effects of adalimumab, a biological systemic therapy, on systemic vascular inflammation in subjects diagnosed with moderate to severe psoriasis, as compared to narrow-band
ultraviolet B phototherapy or placebo. The primary outcome measure is the change in total vascular inflammation in aortic segments as assessed using
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F-fludeoxyglucose (FDG) PET/computer

tomography (CT) between baseline and end of study. The timing of the start of the dissertation
research coincided with the start of the VIP trial, and the opportunity naturally arose to observe and
participate in the analytic planning of the trial. This opportunity eventually evolved into the first two
chapters of this dissertation.
Chapter 2 is inspired by a novel application of FDG-PET/CT to quantify the level of skin inflammation. With the goal to quantify and correlate PET signals with clinical psoriasis severity measures,
skin segmentations need to be superimposed on the FDG-PET images that contain measures of
metabolic activity. A method for image segmentation, or the partitioning of an image into segments
of interest, is devised for the skin using the CT image, where a bivariate threshold (i.e. upper
and lower cutpoints are used) is applied to a binary tissue mask image transformed using a Gaus-
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sian filter. This chapter addresses the performance assessment of bivariate thresholding such as
the interval classification used in the segmentation method. However, after the methodology was
developed, it was noticed that proper co-registration, or alignment, of PET image to the CT segmentations became impossible due to significant movements of the extremities during image acquisition
in the VIP trial. A dataset from serum sodium levels in patients hospitalized for fulminant bacterial
meningitis fit the classification scenario was substituted as the motivating example.
While parallels can be drawn from the classic binary classification scenario and the receiver operating characteristic (ROC) analysis, these classic approaches are inadequate and restrictive for
classification beyond simple univariate binary thresholding. Simple classification scenarios involving thresholding a predictor using a cutpoint offer straightforward assessments of classifier performance using the ROC curve, but in complex scenarios, such as bivariate thresholding, the ROC
curve is not specified. Chapter 2 presents a generalization of the ROC analysis, introduces the
concept of the parameter path in the ROC space of a classification scenario, and defines the optimal ROC (OROC) to identify and assess performance of optimal classifiers. Interval classification,
where a predictor is thresholded using two cutpoints, is used to illustrate the OROC estimation and
show that nonparametric estimation (NPE) procedure simultaneously produces the parameter path
of the optimal classifier. Alternative semiparametric and parametric methods for OROC estimation are presented: the generalized additive model (GAM), and the maximum likelihood estimation
(MLE) based on a profile likelihood. The performance of the NPE, GAM, and MLE in Monte Carlo
simulations and application to the serum sodium dataset are presented.
Chapter 3 covers image normalization, a major topic in quantitative PET. Image normalization is
widely viewed as an essential preprocessing step for quantitative analysis. While great advancements have been made in normalization for magnetic resonance imaging (MRI), quantitative analysis of positron emission tomography (PET) primarily involves the use of standardized uptake values
(SUV) which aim to account for major sources of nuisance variation. However, these units are
highly susceptible to variations in imaging protocol and physiology. A normalization method based
on the application of functional data analysis to image intensity distribution functions is proposed
in this chapter, with the assumption that individual density functions are variations from a template
density function. Warping functions, which transform the template density into individual densities,
capture these variations. By modeling the warping functions using a modified function-on-scalar
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regression, the variations in density functions due to nuisance parameters are estimated and subsequently removed for normalization. This chapter outlines image intensity density normalization
and includes the application to the VIP trial dataset. Additionally, the normalized densities show
correlations with cardiovascular biomarkers that are not present in the original densities.
Chapter 4 presents another interesting PET data problem in the realm of neuroimaging. The problem presents itself in the form of a plot (Figure 4.1) of longitudinal measurements of amyloid-beta
(Aβ) in the brain, using florbetapir-PET. There are striking features that show 1) differences by
genotypes, 2) an outline of a common trajectory function, and 3) possible clustering of subjects
who many have significant delay in Aβ accumulation. Aβ is an important biomarker in AD, and
a general hypothesis exists regarding the functional form of its longitudinal trajectory. Surprisingly,
even with various hypotheses on the shape of Aβ trajectories, no studies have integrated this knowledge in modeling Aβ trajectories, with most analyses instead relying on basic linear mixed effects
models. This chapter describes a new approach using nonlinear mixed effects framework to model
Aβ trajectories as measured by florbetapir-PET in a cohort of patients from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI). The hypothesized functional form of Aβ trajectory is incorporated by
assuming 1) a common trajectory function for all subjects, with variations in the location parameter,
and 2) a mixture distribution for the random effects of the location parameter to address an empirical findings that some subjects may not accumulate Aβ. Using a Bayesian hierarchical model,
group differences are specified into the trajectory parameters. Monte Carlo simulation results are
presented to show the performance of model estimates under various scenarios. Application to the
ADNI data show an estimated difference of 21 years in the onset of Aβ between average and high
risk group based on APOE genotype.
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CHAPTER 2
E STIMATION

OF THE OPTIMAL

ROC

IN COMPLEX CLASSIFICATION SETTINGS

2.1. Introduction
Assessment of classifier performance is well established for simple biomedical scenarios. The most
common methods quantify the tradeoff between correct and incorrect disease classifications to determine the performance of a biomarker, and these methods are prevalent in binary classification
settings. While these methods may be sufficient for classification that involves thresholding a continuous score, they are not be able to accommodate complex classifications such as multivariate
thresholding. In the setting of multiple thresholds, the traditional single threshold method cannot
be used to assess the performance of the classifier. Alternatively, the performance measure of the
classifier must accurately reflect the classification rule.
The receiver operating characteristic (ROC) curve is the standard method of assessing classifier
performance, owing largely to the simplicity of its graphical and statistical interpretation (Metz,
1978; Pepe, 2003). The ROC curve is defined in the binary setting, where two distinct classes
are assumed to have different (i.e. separated) distributions of a common measure such that partial
separation of distributions can be achieved using a single cutoff. In this particular setting, the ROC
curve has been extensively characterized and its properties are well understood.
In the framework of the simple thresholding of a dependent variable that allows the tradeoff between sensitivity and specificity to be used, extensions have been developed for more complex
decision rules, with the emphasis primarily on ternary classification such as trichotomous classification (Dreiseitl, Ohno-Machado, and Binder, 2000; Mossman, 1999) and transitional (ordinal)
classification (Alonzo and Nakas, 2007; Nakas and Alonzo, 2007). These classifier assessment
methods rely on a seemingly natural extension of the ROC curve, the ROC surface, whose volumetric interpretation is similar to the area under the ROC curve (AUC) (Dreiseitl, Ohno-Machado,
and Binder, 2000; Mossman, 1999; Nakas and Yiannoutsos, 2004; Nakas and Alonzo, 2007).
However, traditional ROC analysis suffers the major limitation of an assumption of classification
based on univariate thresholds, i.e. it assumes risk increases or decreases monotonically with the
biomarker. Consider a scenario where the classification is based on a more complex decision rule,
4

such as biomedical image segmentation (i.e. classification of features of an image as anatomical or
disease classes) using a multimodal histogram where a feature of interest has values only within a
specific interval (Chen, 2008). A histogram of the image intensity values may assume a multimodal
distribution, and a segmentation algorithm may partition the histogram using thresholds based on
features such as valleys in the histogram. Another scenario to consider is predicting survival of patients based on biomarkers at admission to a hospital in patients with fulminant bacterial meningitis
(Muralidharan, Mateen, and Rabinstein, 2014), where serum sodium level within a specific range
may predict survival better than using single threshold. In such cases, traditional ROC analysis,
which can only assess the sensitivity and specificity tradeoff for one threshold at a time, are no
longer useful.
We propose a simple generalization of ROC analysis that does not impose a binary cutoff restriction
and can easily accommodate various classification scenarios. In Section 2.2, we introduce optimal
ROC framework and apply this concept using a simple case that involves classification bounded
by two thresholds, or interval classification. We demonstrate nonparametric, semiparametric, and
parametric estimation procedures for the generalized ROC analysis, and show that the nonparametric estimation procedure has the benefit of simultaneously estimating the optimal thresholds for
a given sensitivity or specificity. In Section 2.4, we compare the performance of the various proposed ROC methods in simulation studies. In Section 2.5, we apply these methods to the study of
serum sodium levels for predicting survival in bacterial meningitis patients.

2.2. Description
2.2.1. Classical terminology
We adopt the traditional terminology from the simple binary classification scenario. The true class
membership Y = {1, 0} is predicted using a continuous predictor X. For a given threshold parameter θ, an observation with X > θ is classified as Y = 1. Consequently, the true positive rate (TPR),
or sensitivity, is defined as the proportion of correctly classified positives (denoted as Y ):

TPR(θ) = P (X > θ|Y = 1) = P (XY > θ).
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(2.1)

The false positive rate (FPR), or 1-specificity, is defined as the proportion of incorrectly classified
negatives (denoted as Ȳ ):

FPR(θ) = P (X > θ|Y = 0) = P (XȲ > θ).

(2.2)

While the plot of TPR as a function of FPR(θ) traditionally represents the ROC curve (Pepe, 2003),
we use a more general representation of the ROC as a vector-valued function,

ROC(θ) = {FPR(θ), TPR(θ)}, for θ ∈ Θ.

(2.3)

In traditional binary classification, Θ = R, and the plot is a monotonic curve. Specifically, the ROC
curve is a function of the data generating distribution, the classifier f , and its parameter θ. In
simple classification, the classifier is based on a single parameter θ and it can be summarized as
an indicator function
f (θ, X) = I(X > θ).

(2.4)

The performance of the classifier is summarized using the AUC by integrating TPR over FPR.
2.2.2. Parameter path of the ROC curve and the optimal ROC
The tradeoff between TPR and FPR is graphically summarized by the ROC curve. In the simple
classification scenario, TPR as a function of FPR(θ) is sufficient to describe the performance of the
classifier over Θ as an ROC curve. In the more general case, θ ∈ Θ must be properly structured to
represent a classifier in ROC space.
For a classifier f , we define a continuous path φ,

φ : (0, 1) 7→ Θ,

(2.5)

where lims→0 φ(s) corresponds to (0,0) in the ROC plot, and lims→1 φ(s) corresponds to (1,1).
In the simple classification case, lims→0 φ(s) = −∞ and lims→1 φ(s) = ∞. Conceptually, φ can
be represented as a sequence of θ that plots the ROC curve from (0,0) to (1,1). We denote the
functional space of all φ by Φ, and in simple classification Im(φ) ≡ R, ∀φ ∈ Φ.
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In a given classification schema, Φ produces set of all possible ROC curves. Since it is convention
to attribute one ROC curve to a classifier, from now we refer to φ as a classifier. Revisiting the
ROC, it can now be defined as a function of the classifier and data:

ROC(FY,Ȳ , φ, s) = {FPR(φ(s)), TPR(φ(s))}, s ∈ [0, 1].

(2.6)

Furthermore, we generalize the AUC as the integration of TPR over φ transformed to FPR:
Z
TPR(θ) dFPR(θ) · dθ.

AU C =

(2.7a)

φ

It can be reparameterized as an integral over FPR:
1

Z
AU C =

TPR(φ(s)) dFPR(φ(s)).

(2.7b)

0

In the case where FPR is an invertible function whose domain is φ(s), s ∈ [0, 1], substituting
u = FPR(φ(s)), (2.7b) becomes more familiar:
Z
AU C =

1

TPR(FPR−1 (u)) du.

(2.7c)

0

The concept of the optimal ROC is straightforward. For a given classification scenario in Φ, we are
interested in a classifier φ that achieves the best classification. Namely, we want φ that achieves
the optimal ROC, with optimality defined by a feature (generally the AUC) of the ROC curve:

arg max AU C(φ) := {φ | ∀τ ∈ Φ : AU C(τ ) ≤ AU C(φ)}.

(2.8)

φ

In simple classification, {Im(φ)} ≡ R implicitly defines a unique φ that spans from −∞ to ∞,
therefore it is the optimal ROC classifier.
2.2.3. Interval classification
The concept of optimal ROC may seem trivial in simple classification, but its importance is evident in classification that uses more than a single parameter. To illustrate the optimal ROC, we
describe a more complex classification schema with two real parameters, θ = {θ1 , θ2 }, and with the
7

classification function defined as

f (θ, X) = I(θ1 < X < θ2 ).

(2.9)

We refer to this as interval classification, and the decision rule is also straightforward. In this case,
the TPR is:
TPR(θ) = P (XY > θ1 ∩ XY < θ2 ).

(2.10)

FPR(θ) = P (XȲ > θ1 ∩ XȲ < θ2 ).

(2.11)

Similarly, FPR is defined as

A contour plot of FPR(θ) and TPR(θ) (Fig 2.1) best illustrates Θ, now a subset of R2 , and Φ of
this schema. As before, define a path represented as an arc along the surface with end points
parameterized as 0 and 1, respectively representing (FPR, TPR) of (0,0) and (1,1). Let φ be a
continuous function that maps the arc to the parameters that constitute an ROC curve, such that
lims→0 φ(s) = {θ, θ} for some θ ∈ R and lims→1 φ(s) = {−∞, ∞}. In this scenario, Im(φ) is a set of
θ ∈ R2 that defines an ROC curve. It is evident that a unique φ does not exist; rather, many possible
classifiers exist. The corresponding ROC curves of the four φs highlighted in (Fig 2.2) show a wide
classifier performance range, but φ1 has the largest AUC.
The AUC in interval classification has the following form:
Z
AU C =

TPR(θ) dFPR(θ) dθ
φ

Z
P (XY ≥ θ1 ∩ XY ≤ θ2 )·

=
φ

d{P (XȲ ≥ θ1 ∩ XȲ ≤ θ2 )}dθ.
The conventional interpretation of the AUC is the probability of correctly ordering diseased and
non-diseased in simple classification (Pepe, 2003). This interpretation is more difficult in complex
classification settings; however, for the simple case where FY and FȲ are symmetric about 0 and
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Figure 2.1: Plot of FPR(θ) and TPR(θ). TPR(θ) is the color overlay of FPR(θ), represented as
the surface plot. The colored curves along the surface represent sample φ’s. The black curve
represents the φ of the optimal ROC. The corresponding ROC curves are shown in Figure 2.2. The
plot represents underlying data densities in Figure 2.3a (µ = 2.5).
θ1 = −θ2 for all points along φ, it can be easily seen that

AU C = P (|XY | < |XȲ |),

(2.12)

which is similar to the probabilistic interpretation of AUC in the classical case.

2.3. OROC estimation
We present three methods for estimating the optimal ROC for our interval classification scenario,
but these methods are generalizable to many binary classification scenarios.
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Figure 2.2: ROC curves corresponding to φ’s in Fig 2.1.
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2.3.1. Nonparametric estimation
Ideally, we want to estimate the φ that satisfies the definition of optimality (2.8) for a given classification scenario. From a random sample (X1 , Y1 ), . . . , (Xn , Yn ), we may simultaneously estimate
the φ and optimal ROC curve nonparametrically. Formally, for each possible value of FPR = s, we
choose the parameters θ that have the corresponding FPR and maximum TPR:

b (s) = arg max TPR(θ) := {θ | ∀π : TPR(π) ≤ TPR(θ)}.
φ
Opt

(2.13)

θ:FPR(θ)=s

Monotonicity is guaranteed since FPR(θ1 , θ2 ) ≤ FPR(θ1 − δ1 , θ2 + δ2 ) and TPR(θ1 , θ2 ) ≤ TPR(θ1 −
b (u) is the estimator for φ in (2.8); maximization of TPR over all
δ1 , θ2 + δ2 ) for any δ1 , δ2 > 0. φ
Opt
values of FPR results in maximizing the AUC. Alternatively, for a given value of TPR = s, θ could
also be chosen to have the minimum FPR:

arg min FPR(θ) := {θ | ∀π : FPR(π) ≥ FPR(θ)}.

(2.14)

θ:TPR(θ)=s

The two methods are equivalent and yield the same optimal ROC curve, since TPR for θ̂ obtained
for given value of FPR returns θ̂ by definition, and vice versa.
The nonparametric method simultaneously estimates the classifier φ and the optimal ROC curve.
In the interval classification scenario, φ is represented by a continuous path along the ROC surface
in Figure 2.1, but φ may include any set of discontinuous or disjointed paths that give rise to the
optimal ROC. From this point, we refer to the nonparametric optimal ROC classifier estimation as
NPE. Appendix A is the R code for nonparametric estimation of the optimal ROC AUC.
2.3.2. Semiparametric estimation
An alternative method for estimating the optimal ROC for the interval classification is a generalized
additive model (GAM) using quadratic penalized regression splines with smoothing parameters selected by REML (Hall, Hyndman, and Fan, 2004; Hastie and Tibshirani, 1986) for the classification
of class membership. The model is simply

logit{Pr(Y = 1|X)} = f (X)
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(2.15)

where the function f is a smooth function of X, modeled using thin plate regression splines (Wood,
2003). For interval classification, the general shape of f is a smooth curve with a single hump
centered between the intervals and low values outside of the interval (e.g. a quadratic curve).
The performance assessment of φ is straightforward: the predicted value from (2.15) can be thresholded as in the classical scenario, and a simple area under the ROC curve can be employed to
estimate the optimal ROC. Additionally, f −1 {logit(p̂)} ∈ {Im(φ̂)} so φ can be estimated indirectly,
and we refer to this semiparametrically estimated classifier as the GAM classifier. We implement
this using the R (R Core Team, 2014) package mcgv (Wood, 2000, 2004, 2011).
2.3.3. Parametric estimation
Another alternative method for optimal interval classification is specifying a parametric model. For
our interval classification scenario, we can incorporate the complex decision rule directly into a
generalized linear model and maximize the model likelihood L under

logit{Pr(Y = 1|S)} = α + βI(θ1 < X < θ2 ).

(2.16)

Our parameter of interest is θ = {θ1 , θ2 }. We estimate {θ, α, β} using a profile likelihood Lθ (α̂θ , β̂θ ).
For each θ using a grid search, we find α̂ and β̂. Subsequently, we evaluate

θ̂ Opt = arg max Lθ (α̂θ , β̂θ ),

(2.17)

θ

which we refer to as the MLE classifier. We assess the performance of the MLE classifier using
ROC curve generated from the logistic model or direct classification.

2.4. Simulation
To compare the proposed estimation techniques for the optimal ROC, we simulate from datagenerating distributions consistent with the interval threshold setting, where XY is sandwiched
by XȲ . We first consider symmetric distributions for simplicity using bimixture distributions, and we
then consider estimating φ using asymmetric distributions. The data are independently generated
for training and validation.
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2.4.1. Simulation - symmetric distributions
Three different scenarios are considered for our simulations, with variations in distributional overlap
between XY and XȲ . In the world simulation, we use a normal distribution and a mixture distribution
of normals (Figure 2.3a). For each observations i = 1, ..., N , we randomly sample XY i ∼ N (0, 1),
and for each observations i = N + 1, ..., 2N , we randomly sample XȲ i ∼

1
2 N (−µ, 1)

+ 12 N (µ, 1).

In the second simulation, the distribution of the score for cases is modified to a uniform distribution
(Figure 2.3b). For each observations i = 1, ..., N , we randomly sample XY i ∼ U nif (−1.5, 1.5),
and for each observations i = N + 1, ..., 2N , we randomly sample XȲ i ∼

1
2 N (−µ, 1)

+ 12 N (µ, 1).

The third simulation involves a biuniform distribution flanking a uniform distribution (Figure 2.3c);
the distributional overlap is no longer transitional. For each observations i = 1, ..., N , we randomly
sample XY i ∼ U nif (−1.5, 1.5), and for each observations i = N + 1, ..., 2N , we randomly sample
XȲ i ∼ 21 U nif (−µ − 1.5, −µ + 1.5) + 12 U nif (µ − 1.5, µ + 1.5).
2.4.2. Simulation results
We simulate B = 1000 datasets for each parameter combination and obtained AUC performance
measures for the training and validation sets. Figure 2.4 summarizes the mean AUCs. In all simulations, the AUC increases with greater separation between XY and XȲ (i.e. increasing µ).
While there is a tendency for the NPE to overfit the data when the separation is small (i.e. greater
overlap between XY and XȲ ), more so than the GAM and the MLE, the NPE performs better
than GAM and MLE in small sample sizes and smaller separations in distributions. With sharp
distributions (i.e. uniform, simulations 2 and 3 in Fig 2.4), the NPE once again performs better than
GAM and MLE in smaller sample sizes and separations. In general, the optimal ROCs from NPE
and GAM methods are more similar than those of the MLE method, and this may be attributed to
the estimation of a single point in the MLE φ .
2.4.3. φ estimation
Figure 2.5 illustrates the NPE of φ. We simulated data using asymmetric distributions with the
following parameters: XY i ∼ N (1, 1), XȲ i ∼

1
2 N (−0.5, 1)

+ 12 N (2, 1), and N = 500 each for XY

and XȲ . The estimation procedure according to (2.13) is used.
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Figure 2.3: Simulation densities for XY and XȲ . (a) mixture of normals for fȲ (x) and normal for
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Figure 2.5: ROC curve and φ. Solid and dashed lines represent the truth (the data generating
distributions shown in red and orange) and NPE of the ROC curve and φ.
The NPE ROC curve is remarkably close to the true optimal ROC curve. There is expected noise
b especially at the beginning of the ROC curve, but the overall path is captured. The intervals
in φ,
between θ1 and θ2 in the true and estimated φ are consistent over the values of FPR.

2.5. Serum sodium data
The motivating dataset is from a retrospective study that sought to identify neurological factors
associated with poor outcome in adult patients with fulminant bacterial meningitis (Muralidharan,
Mateen, and Rabinstein, 2014). Serum sodium at admission was obtained in 39 patients hospitalized for fulminant bacterial meningitis at the Mayo Clinic in Rochester, Minnesota. The primary
end-point of the study was in-hospital mortality.
Patients who have serum sodium levels outside of the ideal range of 136-145 mmol/liter may have
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higher risk of poor outcomes (i.e. death) (Kratz et al., 2004), whereas serum sodium levels inside
the ideal range would carry no additional risk of death. With the outcome defined as survival,
we estimate the OROC using the NPE method and compare it with the GAM and MLE methods.
Table 2.1 contains the complete data analyses along with bootstrapped 95% confidence intervals
(n = 1000).
Although the GAM has the highest AUC at 0.83, it was not significantly different from the NPE and
MLE methods (AUCs of 0.76 and 0.69, respectively). It is possible that due to a small sample size,
outliers may force the flexible splines of the GAM to estimate a functional form that is cubic instead
of quadratic in nature, thereby losing the fidelity to the classification decision rule. We also assess
the performance of the different classifiers using subsampling at random at 30% and 50% of the
observed sample size which shows with similar cross-validated results.
NPE
Sampling
Complete
data

GAM

MLE

Tr

Val

Tr

Val

Tr

Val

75.5
(64.3-90.9)

-

82.9
(69.1-99.2)

-

68.6
(63.3-88.0)

-

85.3

61.0

90.2

63.6

83.3

65.1

80.7

66.7

83.5

70.3

76.3

65.8

30%
50%

Table 2.1: Serum sodium analysis: Complete data and mean AUCs (%) from 1000 resamples

2.6. Discussion
We generalize ROC-based performance assessment in complex classification settings by defining
a classifier φ as a path in the ROC space. The example of interval thresholding illustrates the
inherent limitations of applying the traditional binary decision rules associated with ROC curves,
and the OROC offers an easy and intuitive framework to assess performance of interval classifiers.
Unlike the MLE classifier, where only a single classification table can be obtained, the NPE and
GAM classifiers have flexibility in range of classification statistics. The NPE classifier, however, has
the advantage of ease of interpretation; the directly estimated φ plotted over the ROC curve such
in Figure 2.5 provides an intuitive look-up table for the classifier, and simple comparisons of new
measurements to the optimal thresholds is straightforward. This simplicity is desirable in clinical
b the estimated path through Φ, is noisy, but a smooth function
diagnostic setting. In our example, φ,
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may improve estimation of φ.
While GAM has the added benefit of natural accommodation of external covariates, which can be
useful in applications such as tissue segmentation described above, existing methods for covariateadjusted ROC analysis (Janes and Pepe, 2009) may be applicable to the NPE. Furthermore, the
flexibility of the GAM may make it susceptible to influential outliers. This may result in loss of fidelity
to an a priori classification rule, whereas the NPE and MLE methods are bound by the classification rule. Regarding comparison of NPE classifiers, existing tests using bootstrap estimates of
standard errors of the AUCs can be easily performed (Hanley and McNeil, 1982) without being
computationally expensive. Further work is necessary to investigate the asymptotic distribution of
the NPE AUC with and without distributional assumptions.
In addition to improvements in classification performance in data scenarios described in this chapter, the simplicity of the performance measure of complex classifiers should make the application
of NPE and GAM more compelling. The present work uses the bivariate classification setting example, but this methodology may be extended to multiple input scores X1 , X2 , X3 , ... and threshold
parameters θ 1 , θ 2 , θ 3 , .... Another interval thresholding scenario, albeit theoretical, may include
multimodal thresholding, e.g. I(tl1 < S < tu1 ∪ tl2 < S < tu2 ∪ ...), where clusters of intervals for
class membership exist.
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CHAPTER 3
I NTENSITY N ORMALIZATION

OF

PET

IMAGES VIA

D ENSITY WARP R EGRESSION

3.1. Introduction
Biomedical imaging modalities such as magnetic resonance imaging (MRI), computer tomography
(CT), and positron emission tomography (PET) are established cornerstones of qualitative diagnostics that allow visualization of structures and physiological function in healthy and diseased
subjects. Statistics have gradually transformed the use medical imaging from a qualitative to a
quantitative tool, allowing greater discrimination and more comprehensive descriptions of disease
status and prognosis. However, quantitative analysis of biomedical images is challenging due to
the many sources of unwanted variation that confound the signal. These sources range from machine calibration and scan parameters to the patient’s metabolic rate affected by ambient conditions
(Coxson, 2013). Without comparability of measurements, formal statistical inference suffers from
diminished power and potentially strong biases.
Image intensity normalization is generally acknowledged as a key preprocessing step in the analytical pipeline. Various methods exist in the literature, including histogram matching (Nyul and
Udupa, 1999) and intensity normalization with respect to particular regions of interest (ROI) (Shinohara et al., 2014). In the latter example where particular anatomical structures are assumed to have
similar physical consistency, such as the normal appearing white matter or cerebellar gray matter
in the brain, simple z-score statistical normalization successfully removes a significant amount of
nuisance variability due to parameters such as scanner and platform. More often than not, these
benefits are conferred to imaging modalities with high resolutions (e.g. MRI) and well characterized tissue properties (e.g. density). In PET imaging, image resolution is bounded by an inherent
uncertainty of the radionuclide tracer location, image reconstruction is dependent on near-perfect
alignment of a reference image, and tissue-specific intensity is dependent on pharmacokinetics
and physiological state of the body. The standardized uptake value (SUV), a relative measure of
tracer uptake, compensates for the largest sources of signal variation, which include the amount
of injected tracer, patient body weight, and radioactive decay. Summary measures of SUV and
tissue-to-background ratio, which is calculated by dividing each SUV image by the subject’s mean
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SUV in reference tissues, are mainstays in quantitative PET. Increasingly, however, it is becoming
clear that existing normalization methods for PET may be inadequate to handle these sources of
variability (Huet et al., 2015; Keyes, 1995).
In this chapter, we propose a new statistical normalization strategy based on the application of
functional data analysis (FDA) to image intensity distribution functions. FDA has been previously
proposed for analyzing densities by treating empirical density curves as functional data (FD) objects
(Alois Kneip, 2001) and conducting unsupervised analyses to investigate unwanted variation. One
such method directly uses the empirical probability density functions (PDF) as FD objects (Delicado, 2011). Unfortunately, these normalizations suffer from undesirable properties, including the
violation of regularity conditions of the Hilbert space-based methods when applied to density functions (Petersen and Mller, 2016). Outside of image analysis, supervised methods for normalization
using functional data have been proposed, such as functional normalization (funnorm) by Fortin et
al. (Fortin et al., 2014). This method uses simple additive models for quantile functions as FD objects. Unfortunately, coefficients near boundary values (i.e. at 0 and 1) may be subject to increased
uncertainty in estimation when studying quantile functions. The funnorm approach also does not
account for smoothness in the curves, but rather focuses on pointwise regression techniques in the
context of gene expression distributions. We propose a novel FDA approach to density-valued data
that uses a modified function-on-scalar regression applied to image-specific warping functions from
a template density function. This method aims to increase the flexibility to capture more shape variation and reduce estimation uncertainty at boundary limits, while maintaining interpretability and
improving statistical power for detecting group differences.
Our motivating example comes from the Vascular Inflammation in Psoriasis (VIP) Trial, a randomized, placebo-controlled study designed to test the effect of systemic therapy for psoriasis on systemic vascular inflammation as measured by PET/CT. Psoriasis is a common inflammatory disease
that prominently manifests in the skin, but it is also independently associated with many cardiovascular comorbidities. These include myocardial infarctions (MI), stroke, and cardiovascular death
(Gelfand et al., 2006; Ogdie et al., 2015). The underlying inflammatory mechanism in psoriasis
is shared by other diseases that are associated with cardiovascular burden, and lowering systemic inflammation may mitigate the risk. Since inflammation involves biological processes with
high metabolic activity (i.e. glucose consumption (Emami and Tawakol, 2014)), a radionuclide

20

Figure 3.1: Left: PET image. Intensity levels (shown in jet color spectrum) indicate the level of
18
F-FDG uptake in tissue. Right: Corresponding CT image in grayscale. The anatomical structures
are more pronounced, and the intensity levels indicate tissue density.
glucose-analogue,
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F-fludeoxyglucose (FDG), may be used as a biomarker to measure the level

of metabolic activity. Figure 3.1 is a coronal (frontal) plane image view of a PET/CT scan of a
study patient; red regions, including the brain, show tissue with high 18 F-FDG uptake, indicative of
high metabolic activity. Our goal in this work is to improve quantification of systemic inflammation
through improved normalization of the PET image. In the remainder of this chapter, we apply our
normalization to the VIP data and compare the correlation between densities and cardiovascular
biomarkers before and after normalization.
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3.2. Methods
3.2.1. Density-valued data
In PET, the raw unit of measure is radioactivity concentration of becquerels per cubic centimeter
(Bq/cc). This unit reflects the amount of radionuclide tracer concentration (i.e.
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F-FDG) in tissue,

and is the quantitative unit for a given voxel in a PET scan image. We denote the intensity at a given
voxel v as Y (v), which arises from an intensity distribution f . We make fundamental assumptions of
the data that the intensity distribution of a scan for a patient is a realization of a stochastic process
that generates these distributions. We further assume that the variations from a template density
fm are attributable to biological and non-biological factors, and can be modeled statistically.
3.2.2. Warping functions
For each subject i, we define the density-valued image intensity data as the empirical probability
density function fi (x), where x represents image intensity values and ranges. Likewise, we let
Fi (x) represent corresponding cumulative distribution function. We denote the population template
Rx
function by Fm (x) = 0 fm (u)du, and define the warping function wi (x) as the function that maps
Fm (x) to Fi (x). That is, a warping function wi remaps the domain such that

Fm {wi (x)} = Fi (x).

(3.1)

The warping function is represented as a curve, with the identity function wI (x) = x indicating no
warping. To define the template function, we use the depth measure of centrality of a given curve
within a group of curves as defined by Fraiman and Muniz (2001). We use the functional median
of a set of curves, which is defined as the function Fm (x) having the greatest integrated depth.To
assess the systematic effects of sources of variation that are not related to the biological processes
of interest, we next propose to study the warping functions using functional regression models.
3.2.3. Restricted function-on-scalar regression
Following the assumption that the variations from the population mean or template intensity distributions can be explained by biological and non-biological factors, we can model the effects of these
factors using the warpings as the functional responses. We denote by Vi = (Vij )Jj=1 the vector

22

of observed variables that are not of interest for the study; for example, the dose of radionuclide
tracer administered only introduces unwanted variation into the measurements. We further denote
by Xi = (Xik )K
k=1 the vector predictors of interest for subject i. Since CDFs range from 0 to 1, the
warping functions at domain boundaries are restricted to the identity functions. This can be further
simplified by subtracting the wI (x) from wi (x) to yield functional responses ri (x) that are restricted
to 0 at the domain boundaries.
The ri (x) can be modeled as functional responses for regression models with scalar predictors (i.e.
biological and non-biological factors). We employ regression models for functional responses and
scalar predictors (Ramsay, 2005; Reiss, Huang, and Mennes, 2010):

r(x) = Zβ(x) + (x).

(3.2)

In this scenario, x ranges over some finite interval X ⊂ R, and r(x) can be represented as an
N -dimensional functional response vector. The design matrix Z = [X V ] is N × q dimensional,
β(x) = [β1 (x), . . . , βq (x)]T is the functional coefficients vector, and (x) is the functional error vector.
Consider the b-spline basis function representation of r(x),

r(x) = Cθ(x),

(3.3)

where θ(x) = [θ1 , . . . , θK ]T ] is the vector of K b-spline functions and C is an N × K matrix of basis
coefficients. The coefficient functions in (3.2) are then represented as

βk (x) = bk θ(x),

(3.4)

where bk is the basis coefficient vector. The problem reduces to estimating B = (b1 , . . . , bq )T using
this general form of (3.2):
r(x) = ZBθ(x) + (x).

(3.5)

However, for the warping functions to yield proper CDFs, the aforementioned restriction to r(x) must
be implemented. The basis function representation in (3.3) offers a simple solution to implement
the restriction. Given sufficient K basis functions, we modify B and θ(x) by removing the first and
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last b-spline basis components:

0
 K−2 



×
I K−2 


0K−2


B ∗N ×(K−2) = B N ×K

(3.6)

,

K×(K−2)

and
θ ∗ (x) = [θ2 , . . . , θK−1 ]T .

(3.7)

We estimate B ∗ by minimizing the following:
Z

kCθ(x) − ZB ∗ θ ∗ (x)k2 dt +

q
X

Z
λk

[L(b∗k θ ∗ (x))]2 dt.

(3.8)

k=1

The second term is a roughness penalty with a non-negative tuning parameter λ and a linear
differential operator L. We use a second derivative operator for L.
Since the basis functions θ1 and θK only contribute to the functional range at the boundaries of X,
∗

we first estimate B ∗ and then add the zero coefficients, i.e. B̂ = [0K B̂ 0K ]. We calculate the
estimates of coefficient functions β k (x) and their standard errors from B̂ using standard methods
penalized likelihood estimating λ using generalized cross-validation. We implement the restricted
function-on-scalar regression (rfosr) with the aforementioned modifications to the fosr function
(Reiss, Huang, and Mennes, 2010) in the refund package for R (Huang et al., 2015). Appendix B
is the R code for rfosr.
3.2.4. Normalization
We assume that the degree to which an intensity distribution of a particular scan differs from the
population template is captured by the warping functions, and that the modeled estimated coefficient for various factors are additive in nature and can be adjusted for. Our overall approach to
normalization is to regress out the effects of nuisance factors from the warping parameters, and ultimately estimate an intensity distribution Finorm (x) adjusted for the nuisance factors for each image.
Using functional regression, we separate Z and β(x) to K predictors of interest and J nuisance
variables in (3.2):
r(x) = X K β K (x) + V J β J (x) + (x).
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(3.9)

We form the normalized functions,

r̂ norm (x) = r(x) − V J β̂ J (x),

(3.10)

which we use to form the normalized warping function functions ŵnorm (x). Following the warping
function representation (3.1), the we normalize distributions using the normalized warping functions:
F̂inorm (x) = Fm {winorm (x)}

(3.11)

Figure 3.2 illustrates the normalization procedure. First, we convert empirical densities fi (x) (A)
to Fi (x) (B). We choose a template Fm (x) (C) and calculate warping functions wi (x) (D). We then
regress out the nuisance effects on the warping functions and estimate the normalized warping
functions winorm (x) to obtain the normalized density estimates F̂inorm (x) (E) and f˜inorm (x) (F).

3.3. VIP Trial data
3.3.1. Motivating Study
As a proof of concept, we apply our normalization to the VIP Trial PET/CT imaging data and assess
sensitivity to associations between metabolic activity and lipoprotein particle biomarkers known to
be associated with cardiovascular risk (Austin et al., 1988; Gordon et al., 1989). We study the PET
scans, with intensities recorded in standardized uptake values (SUV), defined voxel-wise as

SU V (v) =

I(v)
C/W

(3.12)

where I(v) is the PET scan and W is the weight of the patient. C is the corrected radionuclide
tracer activity, calculated as
C =T ·2

−

tS −tI
t1/2

,

(3.13)

where T is the injected tracer activity, tS is the time of scan, tI is the time of tracer injection, and
t1/2 is the half life. Base 10 logarithm transformation of SUVs are used as primary units due to the
highly skewed distributions of the whole-body voxel SUVs.
One of the trial objectives is to obtain full-body PET/CT scans, but due to scanner limitations,
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Figure 3.2: Normalization workflow. Empirical densities fi (x) (A) are transformed to Fi (x) (B). A
template density Fm (x) (C) is chosen and warping functions wi (x) (D) are estimated. Using a
modified functional regression, normalized warping functions winorm (x) are calculated, which are
then used to estimate the normalized densities Finorm (x) (E) and finorm (x) (F).
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single-pass full-body scans are not available for many subjects and instead the torso and lower
extremities are often scanned separately. To standardize the scanning protocol, we use singlepass PET/CT scans and truncate at the same anatomic landmark for each scan (the femoral head).
Additionally, to eliminate scanner variability, we analyze scans from a single facility at the Hospital
of the University of Pennsylvania. We obtain log SUV densities after removing background using
active contour segmentation of tissue in ITK-SNAP (Yushkevich et al., 2006).
For the model, we choose variables that are known contributors to SUV variability, such as weight,
drug incubation time (i.e. tS − tI ), and radionuclide dose (Boellaard, 2009), as well as plausible
biological factors such as age and sex. Since the underlying disease process is understood to be
associated with systemic metabolic activity and thus disease, we also included the psoriasis area
severity index (PASI), a clinical measure of psoriasis severity, in the model but do not residualize
based on PASI during normalization. Finally, we compare the SUV means before and after normalization, and correlate the means with lipid and inflammatory biomarkers using each density’s mean
as a coarse measure of total systemic inflammation.
3.3.2. Results
Figure 3.3 shows the estimated functional coefficients of the covariates on wi (x), and figure 3.4
shows the densities before and after normalization (N=32). Of the six scalar covariates in the
model, incubation time has the greatest effect on the warping function, whereas FDG dose has the
least effect on the warping function.
Table 3.1 summarizes the association between the SUV density means and biomarkers pre- and
post-normalization (N=30). We use spearman’s ρ as a measure of correlation. None of the original
density means are statistically associated with the various lipoprotein and inflammatory biomarkers.
Employing the proposed normalization, we find LDL cholesterol concentration (LDLc), LDL particle
size (LDLp), very large LDL particle size (vl LDLp), total cholesterol (Tc), and IL-6 to be statistically
significantly associated density means.

3.4. Discussion
We introduce a new intensity normalization method for quantitative biomedical images using functional regression of density warping functions. Our method models the intensity distributions as
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Figure 3.3: Coefficient functions of the restricted function-on-scalar regression using six covariates.
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Biomarker
HDLc
HDLp
HDLz
S HDLp
M HDLp
LM HDLp
L HDLp
IDLp
LDLc
LDLp
LDLz
S LDLp
L LDLp
VL LDLp
VLDLp
VLDLz
S VLDLp
M VLDLp
LM VLDLp
L VLDLp
VLDLtg
Efflux value
Tg
Tc
LPIR
CRP
IL-6

Original
ρ∗
p-value
17
0.38
3
0.87
3
0.89
-23
0.22
10
0.59
16
0.40
20
0.30
-11
0.55
16
0.40
10
0.59
20
0.29
-1
0.94
31
0.10
8
0.68
-23
0.22
-0.00
0.99
-32
0.08
-9
0.62
-11
0.56
-9
0.64
-15
0.43
20
0.31
-14
0.47
16
0.40
-2
0.92
-9
0.62
-30
0.10

Normalized
ρ∗ p-value
10
0.61
-1
0.97
0
1.00
-22
0.23
8
0.66
13
0.49
16
0.39
9
0.63
44
0.02
46
0.01
2
0.91
29
0.11
28
0.13
44
0.01
1
0.97
22
0.25
-22
0.24
17
0.37
17
0.37
8
0.68
12
0.53
13
0.52
16
0.41
39
0.03
17
0.37
-6
0.77
-37
0.05

Table 3.1: Correlation between density means and various lipoprotein particle biomarkers. Abbreviations: HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; Tg, triglyceride; Tc, total cholesterol; LPIR, lipoprotein insulin resistance score; S, small; M,
medium; LM, large-to-medium; L, large; VL, very large. CRP, C-reactive protein; IL-6, Interleukin 6.
Suffixes: z, size; p, particle number; c, cholesterol concentration. ∗ ρ × 100 are shown.
functions of nuisance imaging protocol parameters and removes their effect. By modifying the
b-spline functional basis, we restrict the warping functions to yield proper density functions for normalization. One of the strengths of our method is that it allows the use of full scan intensity densities
instead of using tissue-specific densities. Additionally, since we normalize the entire densities, the
use of reference tissues is not required.
Our application to the VIP Trial data shows promise that normalization may reveal signals that may
otherwise be obfuscated by nuisance parameters. This is extremely important for PET imaging,
where numerous imaging and pharmacokinetic parameters are found to be contributing to SUV
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variability. The regression model indicates that the standardization using the SUV did not adequately “standardize” the effects of the imaging parameters, in particular the FDG incubation time.
Increases in SUV have been noted with increases in FDG incubation time (Basu et al., 2007), with
standardizing the scan initiation time suggested as a corrective measure. In multi-site studies, these
corrective measures such as these may fall short due to the complex nature of PET/CT acquisition
and a statistical normalization may offer the best standardization.
While we have assessed our normalization in terms of association of the density means to lipoprotein biomarkers, another indicator for the usefulness of normalization would be to assess the primary outcomes of the VIP Trial, which are mean PET signals in the aorta. The density means
may offer a measure of cardiovascular risk via systemic inflammation, but they may also oversimplify the relationship between metabolic activity of the entire body and an inflammatory disease
process. Targeted quantification of the aorta using manual segmentations directly assesses the
atherosclerotic burden, and the use of normalized images, i.e. applying winorm and using Y norm (v),
has the potential to improve dose-response and/or treatment effect signals. It is noteworthy, however, that LDL cholesterol concentration and particle size, which are associated with cardiovascular
disease (Sacks and Campos, 2003), are correlated with normalized density means. Our findings
are suggestive of stronger whole-body FDG signal throughout the body in patients with unhealthy
lipoprotein profiles. The significance of the weak inverse correlation of IL-6 and whole-body FDG
signal remains unclear, as IL-6 is implicated in pro- and anti-inflammatory processes (Scheller et
al., 2011).
The overall goals of normalization should be the comparability of quantitative imaging units for
population-level analysis, and the statistical principles of image normalization (Shinohara et al.,
2014) provide guidelines for image normalization. Although the proposed methodology is theoretically consistent with these principles, further work is required to empirically assess the conformity
of our normalization process to these guidelines in large multi-center studies. Some assessments
are straightforward, such as testing the monotonicity of warping functions to assess the intensity
rank preservation. Preserving a similar distributions for similar tissues of interest may be more
challenging when a disease process may affect the distributions of every tissue class, such as the
systemic inflammatory process associated with psoriasis. Future extensions of our work will be developed to normalize scans over time to assess treatment effects, especially when the treatments
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may affect the signal densities. Disentangling treatment effects in a tissue of interest from its effect
on the overall scan is paramount, and functional mixed effect-based models may be appropriate for
modeling the warping functions these settings.
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CHAPTER 4
N ONLINEAR

MIXED EFFECTS MODELING OF AMYLOID -β TRAJECTORIES IN

PET

IMAGING

4.1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive dementia unrelated to normal aging. The disease onset, or time of first symptoms, varies from person
to person, but the the disease progression is consistently characterized by accumulation of amyloid plaques in extracellular space between neurons and neurofibrillary tangles inside neurons. It
is believed that these characteristic structural features disrupt normal brain function and lead to
loss of neurons. Of interest is how these physical changes in the brain progress over time and
correlate with progression of disease. Accurately measuring amyloid-beta (Aβ) protein levels, the
components of amyloid plaques, is important in understanding the plaque burden as well as stage
of disease progression. In-vivo imaging of these structures may enable earlier AD diagnosis and
guide therapeutic regimens.
There is strong evidence that Aβ PET imaging is a promising biomarker of brain Aβ-plaque load
(Kepe et al., 2013). Currently there are two PET imaging compounds for Aβ: 1) Pittsburghcompound B (PiB) (Klunk et al., 2004), and 2) florbetapir (Clark et al., 2011), and both radionuclide tracers bind to Aβ plaques in the brain. While PET applications using PiB has been around
since the early 2000’s, the more recent florbetapir has a favorable half-life profile (109.8 min in 18 F
florbetapir compared to 20.38 min in 11 C PiB), which allows an easier imaging protocol.
Several trajectory shapes of major AD biomarkers have been theorized, and they generally are
based on the sigmoidal model (Caroli and Frisoni, 2010; Jack et al., 2010). However, their use
in charactering Aβ PET biomarker trajectories is limited; linear mixed effects (LME) models are
generally the basis of longitudinal trajectory modeling (Jack et al., 2012; Resnick et al., 2010,
2015). In the context of a sigmoidal trajectory model, the obvious limitation of LME model is the
nonlinearity of the hypothesized trajectory; linearity is assumed once a threshold is reached (i.e.
Aβ-positivity), but the baseline (bottom plateau) and Aβ saturation (upper plateau) are not properly
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accounted for.
In this chapter, we propose a new method of modeling the Aβ trajectories based on a couple of
biological assumptions. The first assumption is that each subject has a unique Aβ trajectory based
on a common functional form (i.e. sigmoidal curve). The second assumption is that there are subjects for whom the accumulation is not observed. In Section 4.2, we incorporate these assumptions
by combining a nonlinear mixed model framework with mixture of heterogeneous populations, and
formulate the trajectory model in a Bayesian framework. In Section 4.3, we evaluate the performance of the Bayesian model in estimating the parameters using Monte Carlo simulation studies.
In Section 4.4, we apply these methods to the florbetapir dataset from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) cohort for estimating group differences in Aβ trajectories.
4.1.1. ADNI data
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a consortium of researchers whose goal
is to collect, validate, and utilize study data to define the progression of AD. MRI and PET study
data are used, in addition to genetics, cognitive tests, and CSF/blood biomarkers, to understand
and predict AD. Florbetapir PET imaging has been collected in a cohort of subjects with ADNI,
which is publicly available (adni.loni.usc.edu).
The unit of Aβ florbetapir measure is the standardized uptake value ratio (SUVR), which is the
nonweighted SUV average across four main cortical regions (frontal, anterior/poster cingulate, lateral parietal, lateral temporal) divided by the SUV average across the composite reference region
(whole cerebellum, brainstem/pons, and eroded subcortical white matter) (Landau et al., 2015).
Figure 4.1 is a spaghetti plot of the Aβ trajectories in the ADNI cohort as measured by PET imaging. To illustrate genetic differences, four color groups indicate the different AD risk profiles based
on APOE gene alleles. Typically, there are two to three Aβ measurements per subject, with an
average time between subsequent scans being 2 years. Due to radiation toxicity and cost of scans,
repeated measurements throughout the course of Aβ accumulation are not performed.
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Figure 4.1: Trajectories by APOE risk category and overlay of proposed trajectories

4.2. Methods
4.2.1. Assumptions
As mentioned previously, we make several assumptions about Aβ trajectories:
1. An individual has a unique Aβ trajectory that follows a common trajectory shape
2. An individual may or may not exhibit Aβ accumulation
The first assumption is based on the literature of AD biomarkers that indicate Aβ accumulation is a
common biological phenomenon in all subjects. The AD disease progression is associated with Aβ
accumulation in the brain, from a baseline value corresponding to a healthy level to an upper value
corresponding to a saturated Aβ level. However, healthy, nondemented individuals are subject to
accumulation of Aβ (Braak and Braak, 1991), and amyloid plaque load does not correlate well with
the degree of cognitive impairment (Hardy and Selkoe, 2002). Sections 4.2.2 and 4.2.3 describe
the common trajectory and its model framework.
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The second assumption is based on the observation that many subject-level trajectories do no
accumulate over time and stay at a baseline level (i.e. flat) far into the observation window, even
in subjects who are at higher risk of AD. In the context of the first assumption, it is plausible that,
given adequate follow-up without censoring due to death, an individual will exhibit the characteristic
accumulation of Aβ. Section 4.2.4 incorporates the second assumption into the model framework.
4.2.2. Trajectory function
The prevailing trajectory shape for cortical Aβ accumulation is the sigmoidal curve (Jack et al.,
2010). Under assumptions discussed by these authors, each subject’s Aβ trajectory follows a
common sigmoidal curve, and the general model for Y (t), the SUVR measurement at time t, is of
the form
Y (t) = A +

K −A
,
1 + e−B(t−M )

(4.1)

which is the generalized logistic function. The parameters are as follows: A - lower asymptote; K
- upper asymptote; B - shape/slope parameter; M - location parameter. In terms of Aβ trajectory,
A describes the baseline (i.e. pre-accumulation) level of Aβ, and K is the limit of Aβ capacity of
the brain. M describes the time of the inflection point and thereby is the parameter of onset of Aβ
accumulation. It should be noted that M is not interpreted as the time of onset of accumulation;
rather, M and B together determine the time of accumulation onset (i.e. start of the exponential
growth phase).
4.2.3. Nonlinear mixed effects model
Nonlinear mixed effects models, or hierarchical nonlinear model, provide a flexible framework when
linear mixed effects models are inadequate (Marie Davidian, 2003). We follow this framework to
model the outcome data. Let Yij be a response variable for florbetapir SUVR, the biomarker for
Aβ, at tij , the jth time measurement in age, for the ith subject for i = 1, . . . , n. Additionally, let
mi and ai be the subject-specific location and lower asymptote parameters for the ith subject. The
subject-specific model of the response variable is as follows:

Yij = ai +

K − ai
+ ij ,
1 + e−B(tij −mi )
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(4.2)

with

ai ∼ U nif (AL , AU ),
2
mi ∼ N (M, σM
),

ij ∼ N (0, σ2 ).

M is the population-level parameter of Aβ onset, and we assume subject-level parameters are
normally distributed about M . Subject-level baseline of Aβ is assumed to be uniformly distributed
within the clustered observations. Furthermore, this model assumes conditional, or serial, independence (i.e. ij ⊥ ik | ai , mi ). We ignore serial correlation as its effects are often dominated by the
combination of random effects and measurement error (Verbeke and Molenberghs, 2001).
4.2.4. Mixture distribution
We define accumulators (G = 1) as subjects whose observed Aβ trajectories have a positive slope,
and non-accumulators (G = 0) as subjects whose observed Aβ trajectories are flat at baseline
during the observation period. By our first assumption, all subjects have a common sigmoidal Aβ
curve, so we address the second assumption of non-accumulation of certain subjects by introducing
a shift in M such that the exponential growth portion (i.e. Aβ accumulation) is not observed in the
age range. The mixture distribution of mi is the following:
2
2
mi ∼ π × N (M1 , σM
) + (1 − π) × N (M0 , σM
),
0
1

(4.3)

where π is the probability of accumulator membership P (G = 1), and M1 and M0 are the Aβ onset
parameter group means of the accumulators and non-accumulators, respectively. Furthermore, π
can be modeled based on subject-specific risk profiles such as a high-risk allele of a known gene,
e.g.:
n
o
logit π|X = x = β0 + βx,
where X = {0, 1} is a binary variable for a high-risk allele.
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(4.4)

4.2.5. Group differences in Aβ onset
Another implicit assumption is that there is a group difference in Aβ onset based on risk profiles
(e.g. genetic). This is a widely accepted concept with strong biological foundations and empirical
data. Let δ be the group difference in the population-level parameter M between two risk groups.
Then the subject-specific random effects for Aβ onset is distributed as follows:

2
mi ∼ N (M + δxi , σM
),

(4.5)

where X = {0, 1} is a binary variable for risk group. The hypothesis testing of the group differences
is simply:
H0 : δ = 0
vs

(4.6)

Ha : δ 6= 0.

4.2.6. Bayesian estimation
Bayesian formulation of the model offers a tractable estimation subject-level parameters (e.g. mi )
and inference (e.g. π, δ). Moreover, it allows incorporation of known constraints to model parameter
values with prior distributions. Treating the parameters as random variables, we approximate a joint
posterior density by sampling these parameters using MCMC techniques. We simulate the posterior
densities using a Gibbs sampler implemented in R (JAGS - Just Another Gibbs Sampler ; Plummer
et al., 2006). Appendix C is the BUGS model specification (Lunn et al., 2000).

4.3. Simulation
We evaluate the performance of the proposed inference using simulation studies. In all simulations,
the truth is simulated as in model XX to mimic the ADNI dataset. Unless otherwise stated, each
simulation consists of M=500 simulated replicates with N=300. Each replicate is run with 11,000
iterations with 1,000 burn-in.
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Figure 4.2: Simulated data per simulation 1a. The color gradient indicates the proportion of the
subject being sampled as an accumulator.

4.3.1. Simulation 1 - Estimation of accumulation
The goal of these simulations is to evaluate the performance of the model in estimating the proportion of accumulators and predicting the accumulators. We simulate the truth model with normal
random effects distributions, m1i ∼ N (75, 102 ), m0i ∼ N (500, 102 ), a uniform random effect distribution, ai ∼ U nif (0.65, 0.75), a fixed π, K = 1.2, B = 0.15, and Yij based on (4.2). For each i,
age at observation is sampled uniformly from 50 to 90, with 2 or 3 measurements generated with
a probability of 0.50 each, and measurements intervals from N (2, 0.12 ). Figure 4.2 is a plot of the
data simulated per simulation (a) in Table 4.1, with the color gradient indicating the proportion of
the observation being sampled as an accumulator.
Table 4.1 summarizes the various performance measures with varying simulation conditions. In
simulation 1a, the Bayesian model is specified as the simulation condition. In simulations 1b and 1c,
we introduce misspecification to B and A in the model, where B = 0.3 and ai ∼ U nif (0.55, 0.85),
respectively. The proportion is altered in simulations 1d and 1e, and σ is increased in 1f and 1g to
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induce noise. In set 1h, the data are generated to reflect K = 0.8 and are modeled as 1a.
In nearly all simulation scenarios, the Bayesian posterior parameter means reflect the truth, with
the exceptions in simulation 1h. π and σ are slightly under- and overestimated, respectively. The
AUC is for the classification of accumulators based on the probability score of being an accumulator, calculated as proportion a subject is sampled as such per replicate run (i.e. 10,000 random
sampling). In all scenarios with the exception in 1h, there is good classification performance, with
average AUC of 0.95.
4.3.2. Simulation 2 - Group differences
Next we consider a scenario where there are two groups, each with a different mean onset of
Aβ accumulation. The data-generating model now consists of two groups which we denote by
X = {0, 1}. We simulate data normal random effects distributions, m1i ∼ N (75 + δxi , 102 ) and
m0i ∼ N (500, 102 ), and gi is sampled according to (4.4), with fixed effects β0 and β. Additionally,
we proceed as in the first simulation scenario with ai ∼ U nif (0.65, 0.75), K = 1.2, B = 0.15, and
Yij is sampled using (4.2). Again, for each i, age at observation is sampled uniformly from 50 to 90,
with 2 or 3 measurements generated with a probability of 0.50 each, and measurements intervals
from N (2, 0.12 ).
Table 4.2 summarizes various simulation scenarios. The simulated differences are at 15 years, 5
years, and 1 year, with varying parameters for β0 and β1 . In all scenarios, the model estimates of δ
correspond closely with the truth, indicating excellent model performance.

4.4. ADNI florbetapir data
The analytic ADNI florbetapir dataset contains a total of 1348 observations from 236 controls, 301
MCI, and 79 AD subjects, with each subject contributing from 2 to 3 observations over time. Data
were processed and summarized as described in Landau et al. (2013). The mean age at baseline
scan is 73.2 years, and the mean interval between scans is 2.1 years. Using the APOE gene allele
data, four risk categories are assigned (Slooter et al., 1998), from lowest to highest: 1 - ε2/ε2 or
ε2/ε3; 2 - ε3/ε3; 3 - ε2/ε4 or ε3/ε4; 4 - ε4/ε4. Figure 4.1 shows the data stratified by APOE risk
status. Group 2 is at average risk of developing AD.
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For the analysis, sixty one subjects in the below-average risk category (group 1) are excluded,
leaving 1211 observations from 555 subjects. For each subject i, the risk classification is binarized
to high risk (groups 3 and 4) and average risk (group 2), denoted by the variable AP OEi . We
denote Yij the florbetapir SUVR measured at tij . We consider the hierarchical model based on
(4.2), (4.3), and (4.4).
2
We fit the Bayesian model by assuming a N (M1 , σM
) distribution for m1i , with hyperpriors M1 ∼

N (75, 104 ). For m0i , we assume a fixed distribution of N (500, 1) to reinforce the non-accumulators.
For β0 and β1 , we assign N (0.5, 1) and N (0, 1) priors, respectively. Additionally, we specify ai ∼
U nif (0.6, 0.8), K = 1.1, and B = 0.15.
The posterior means of the estimates are summarized in Table 4.3. The model estimates a mean
difference of 21 years between the two APOE groups, with the lower risk group having a mean Aβ
onset parameter of 90. The 95% credible interval of δ precludes the null hypothesis that δ = 0. The
parameters for (4.4) indicate that the Figure 4.3 show the data with the mean group trajectory for
high risk (red line) and normal risk (orange line), with the color gradient indicating the proportion of
the subject being sampled as an accumulator.
As an exploratory analysis, another gene associated with AD is investigated. Bridging Integrator 1
(BIN1) has been associated with AD, particularly with late-onset AD (Naj et al., 2011, 2014), and
the SNP data for BIN1 (rs7561528) is readily available in a subset of ADNI florbetapir cohort. For
the analysis, there are 675 observations from 297 subjects who have the SNP genotyped. For each
subject i, the genotype is binarized to A/A and non-A/A (i.e. A/G, G/G). Denoted by the variable
BIN 1i . The same model specifications are used as above.
The model estimates are summarized in Table 4.4. The model estimates a mean difference of 3.5
years between the two BIN1 groups, but the 95% credible interval includes the null value of 0, and
the non-A/A group had an estimated mean Aβ onset parameter of 80.

4.5. Discussion
We propose a framework for Bayesian inference in nonlinear mixed models for characterizing
biomarker trajectories and estimating group differences while incorporating a mixture distribution
for random effects. This approach has several advantages over the more conventional linear mixed
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Figure 4.3: ADNI mean trajectories by APOE risk group. The red curve is the mean trajectory for
the high risk group, and orange curve for the normal risk group. The color gradient indicates the
proportion of the subject being sampled as an accumulator.
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effect models including that the hypothesized longitudinal trajectory function is directly incorporated
into the model and prior distributions can be used to inform known constraints on model parameters. By formulating the hierarchical models, this approach also identifies group differences based
on functional parameters that have simple biological interpretation, such as the shift in the onset of
biomarker accumulation.
To our knowledge, this is the first nonlinear modeling method applied to AD biomarkers based on Aβ
accumulation dynamics. Simulation results show that this modeling approach may be able detect
group differences in trajectories as small as one year in delayed accumulation. When applied to
the ADNI data, we identify a difference of 21 years of average onset of Aβ accumulation between
high- and average-risk group based on APOE genotype. An exploratory analysis of BIN1 indicated
a difference average onset of 3.5 years but was not statistically significant.
Some limitations remain with our proposed approach. In our modeling framework, some parameters are fixed a priori, such as the sigmoidal slope parameter B. The prespecified value for B is
based on the aggregate shape of the trajectories and previous reports. Due to the sparseness of
individual measurements in the ADNI dataset (2 to 3 within a span of 4-6 years), model estimation
of B may not accurate. While we show the misspecification of B from 0.15 to 0.3 did not affect
the estimate of π in simulation scenario 1b, additional sensitivity analysis are necessary to determine effect of grossly misspecifying B. To estimate B, more individual measurements that span the
baseline, growth, and plateau phases of the sigmoidal trajectory curve will be necessary. Sensitivity
analyses are also necessary to determine the sparseness threshold for accurate estimation of the
parameter. Furthermore, the assumption of a fixed slope parameter is a strong one, as individuals may exhibit different rates of accumulations. This may be addressed by incorporating random
effects for the slope parameter.
The flexibility of our approach may be useful to model biomarkers with similar nonlinear functional
trajectories, particularly in settings where limitations exist in data acquisition. While our examples
are limited to two group differences, additional factors may be incorporated to explore biomarker
trajectory interactions between APOE status and sex (Altmann et al., 2014). Other trajectory parameters such as the lower and upper asymptotes may also be modeled with appropriate link functions
in a hierarchical manner.
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0.049

0.500

0.622

0.667

0.458
0.452

0.447

0.500

0.500
0.500

0.510

0.500

0.230

0.462

0.500

0.250

π̂

π

0.100

0.030
0.050

0.010

0.010

0.010

0.010

0.010

σ

0.021

0.031
0.051

0.011

0.012

0.014

0.017

0.011

σˆ

0.010

0.023
0.025

0.014

0.023

0.051

0.023

0.019

RMSE(â)

11.540

7.985
8.301

8.983

6.702

8.624

8.219

7.709

RMSE(m̂)

0.656

0.945
0.935

0.955

0.957

0.931

0.959

0.956

AUC

Table 4.1: Simulation 1 results. M=500 for each simulation set, with N=300 per simulation. RMSE: root-mean-square error; AUC: area under
ROC curve.

Scenario
Correctly specified
(a)
B misspecified
(b)
A misspecified
(c)
More accumulators
(d)
More non-accumulators
(e)
Increased noise
(f)
(g)
K Misspecified
(h)
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74.973
74.982

(f)
(g)

1

5

15

15

15

5

15

δ

1.048

4.855

14.498

14.482

14.540

4.919

14.743

δ̂

1

1

1

1

-1

1

1

β0

1.044

0.947

1.053

0.968

-0.894

1.020

1.050

βˆ0

1

0.2

1

0.2

1

1

1

β

0.932

0.269

0.967

0.286

0.883

0.957

0.936

β̂

0.010

0.010

0.010

0.010

0.010

0.010

0.010

σˆ

0.024

0.023

0.024

0.022

0.016

0.024

0.023

RMSE(â)

5.243

5.902

5.274

6.668

8.665

5.450

6.046

RMSE(m̂)

Table 4.2: Simulation 2 results. M=500 for each simulation set, with N=300 per simulation.

75.061

(e)

75.317

(c)
75.161

75.007

(b)

(d)

75.038

M̂

(a)

Scenario

0.966

0.958

0.941

0.915

0.925

0.954

0.913

AUC

M1
σM1
δ
β0
β1
σ

mean
90.318
16.741
-20.705
2.492
1.453
0.027

sd
1.711
0.961
1.994
0.677
0.746
0.001

50%
90.359
16.705
-20.708
2.471
1.449
0.027

2.5%
86.791
14.958
-24.668
1.236
0.016
0.026

97.5%
93.538
18.711
-16.766
3.870
2.966
0.029

Table 4.3: ADNI Bayesian model estimates using APOE

M1
σM1
δ
β0
β1
σ

mean
80.012
19.929
3.460
1.655
0.081
0.025

sd
2.705
1.972
4.633
0.558
0.821
0.001

50%
80.104
19.852
3.565
1.600
0.041
0.025

2.5%
74.493
16.165
-5.866
0.700
-1.376
0.023

97.5%
85.069
23.960
12.353
2.921
1.856
0.026

Table 4.4: ADNI Bayesian model estimates using BIN1
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APPENDIX A
R

CODE FOR

NPE

ESTIMATION OF

OROC ( INTERVAL

CLASSIFICATION )

# function for nonparametric estimation of OROC and ML estimator of a and b
oroc. ll <− function(x,y,cut=100) {
if (length(x)!=length(y)) stop(’Lengths of X and Y differ.’)
# regularized cutoff points
cutoffs <− rev(seq(min(x), max(x), length=cut))
sum.y0<−sum(y==0)
sum.y1<−sum(y==1)
# Internal functions for FPR and TPR
fun. fpr<−function(a,b) {
fpr<−c(sum(x[y==0]>=a & x[y==0]<=b)/sum.y0)
return(fpr )
}
fun. tpr<−function(a,b) {
tpr<−c(sum(x[y==1]>=a & x[y==1]<=b)/sum.y1)
return(tpr )
}
# function for likelihood for ME
fun. ll <−function(a,b) {
s <− (1*x>=a & x<=b)
aic<−glm.fit(cbind(1,s),y,family=binomial())$aic
return(−(aic−4)/2)
}
a<−b<−fpr<−tpr<−ll<− vector()
# grid search
for( cutoff in cutoffs ) {
fpr<−c(fpr,sapply(rev(cutoffs[cutoffs>=cutoff]),fun. fpr ,a=cutoff) )
tpr<−c(tpr,sapply(rev(cutoffs[cutoffs>=cutoff]),fun. tpr ,a=cutoff) )
ll <−c(ll,sapply(rev(cutoffs[ cutoffs >=cutoff]) ,fun. ll ,a=cutoff) )
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a<−c(a,rep(cutoff,sum(cutoffs>=cutoff)))
b<−c(b,rev(cutoffs[cutoffs>=cutoff]))
}
tpr [ tpr<0 | is .na(tpr) ] = 0
fpr [ fpr<0 | is .na(fpr) ] = 0
orcdata<−data.frame(a,b,tpr,fpr,ll)
mle<−orcdata[sample(which(orcdata$ll==max(orcdata$ll)),1),1:2]
# estimation of parameter path
orcdata<−orcdata[order(orcdata$fpr,−orcdata$tpr),]
orcset <− data.frame(orcdata[1,])
for( i in 1:dim(orcdata)[1]) {
if (orcdata[ i ,4]>orcset[dim(orcset) [1],4] &
orcdata[ i ,3]>=orcset[dim(orcset) [1],3]) {
orcset <− rbind(orcset,orcdata[i ,])
}
}
# Trapezoid Rule Numerical Integration
auc<−trapz(c(0,orcset$fpr,1),c(0,orcset$tpr,1))
return( list ( ”orcset”=orcset,”auc”=auc,”mle”=mle))
}

# function for applying optimal cutoffs to validation set
oroc. validation <− function(x,y,rocdata) {
sum.y0<−sum(y==0)
sum.y1<−sum(y==1)
# Internal functions for FPR and TPR
fun. fpr<−function(a,b) {
fpr<−c(sum(x[y==0]>=a & x[y==0]<=b)/sum.y0)
return(fpr )
}
fun. tpr<−function(a,b) {
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tpr<−c(sum(x[y==1]>=a & x[y==1]<=b)/sum.y1)
return(tpr )
}
fpr<−tpr<−vector()
for( i in 1:length(rocdata$a)) {
fpr<−c(fpr,fun.fpr(a=rocdata$a[i],b=rocdata$b[i]))
tpr<−c(tpr,fun.tpr(a=rocdata$a[i],b=rocdata$b[i]))
}
tpr [ tpr<0 | is .na(tpr) ] = 0
fpr [ fpr<0 | is .na(fpr) ] = 0
fpr <− c(0,fpr,1)
tpr <− c(0,tpr,1)
rocdata<−data.frame(fpr,tpr)
rocdata<−rocdata[order(rocdata$fpr,rocdata$tpr),]
auc <− trapz(rocdata$fpr,rocdata$tpr)
return(auc)
}
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APPENDIX B
R ESTRICTED

FUNCTION - ON - SCALAR REGRESSION CODE

# Restricted function−on−scalar regression, modification of fosr (Reiss et al . 2010)
# Modification are highlighted
rfosr <−function(formula = NULL, Y = NULL, fdobj = NULL, data = NULL,
X, con = NULL, argvals = NULL, method = c(”OLS”, ”GLS”, ”mix”),
gam.method = c(”REML”, ”ML”, ”GCV.Cp”, ”GACV.Cp”, ”P−REML”, ”P−ML”),
cov.method = c(”naive”, ”mod.chol”), lambda = NULL, nbasis = 15,
norder = 4, pen.order = 2, multi .sp = ifelse (method == ”OLS”, FALSE, TRUE),
pve = 0.99, max.iter = 1, maxlam = NULL, cv1 = FALSE, scale = FALSE) {
## MODEL BASED ON FOMULA
if ( !is . null(formula)) {
if (is . null(data))
stop(”Please specify the data.”)
tf <− terms.formula(formula)
trmstrings <− attr(tf , ”term.labels” )
terms <− sapply(trmstrings, function(trm) as.call(parse(text = trm)) [[1]],
simplify = FALSE)
responsename <− as.character(attr(tf, ”variables”) [2][[1]])
Y = data[, responsename]
X = model.matrix(formula, data = data)
}
## DEFINE FUNCTIONAL DATA (RESP.TYPE)
if (is . null(Y) == is.null( fdobj) )
stop(”Please specify ’Y’ or ’ fdobj ’, but not both”)
resp.type <− if (is . null(Y))
”fd”
else ”raw”
## ARGVALS
if (is . null(argvals))
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argvals <− if (is . null(fdobj ) )
seq(0, 1, length = ncol(Y))
else seq(min(fdobj$basis$range), max(fdobj$basis$range),
length = 201)
## METHOD
method <− match.arg(method)
cov.method <− match.arg(cov.method)
gam.method <− match.arg(gam.method)
if (method != ”OLS” & (length(lambda) > 1))
stop(”Vector−valued lambda allowed only if method = ’OLS’”)
if ( !is . null(lambda) & multi.sp)
stop(”Fixed lambda not implemented with multiple penalties”)
if (method == ”OLS” & multi.sp)
stop(”OLS not implemented with multiple penalties”)
## BSS, BMAT, RESPMAT
if (resp.type == ”raw”) {
bss = create.bspline.basis(range(argvals), nbasis = nbasis, norder = norder)
Bmat <− Theta <− eval.basis(argvals, bss)
respmat <− Y
}
else if (resp.type == ”fd” ) {
if ( !is . fd( fdobj) )
stop(”’ fdobj ’ must be a functional data object”)
bss = fdobj$basis
nbasis = bss$nbasis
Theta <− eval.basis(argvals, bss)
C = t( fdobj$coefs)
J = getbasispenalty(bss, 0)
svdJ = svd(J)
Bmat <− J12 <− svdJ$u %*% diag(sqrt(svdJ$d)) %*% t(svdJ$u)
respmat <− C %*% J12
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}
## DEFINE INITIAL PARAMETERS AS NULL
newfit = U = pca.resid = NULL
## INITIAL COVARIATE DESIGN
X.sc = scale(X, center = FALSE, scale = scale)
q = ncol(X)
ncurve <− nrow(respmat)
## PEN
if ( multi .sp) {
pen = vector(” list ” , q)
for ( j in 1:q) {
one1 = matrix(0, q, q)
one1[j, j ] = 1
pen[[ j ]] = one1 %x% getbasispenalty(bss, pen.order)
}
}
else pen = list (diag(q) %x% getbasispenalty(bss, pen.order))
################### <MODIFICATION> ###################
## MODIFY BMAT AND PEN
excl .basis <− 1
Bmat <− Bmat[,(excl.basis+1):(dim(Bmat)[2]−excl.basis)]
Theta <−Theta[,(excl.basis+1):(dim(Theta)[2]−excl.basis)]
pen = list (diag(q) %x% getbasispenalty(bss, pen.order)[2:9,2:9])
################### <\MODIFICATION> ###################
## METHOD
constr = if ( !is . null(con))
con %x% diag(nbasis)
else NULL
cv = NULL
if (method == ”OLS”) {
if (length(lambda) != 1 | cv1) {
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################### <MODIFICATION> ###################
lofo <− new.lofocv(respmat, X.sc %x% Bmat, S1 = pen[[1]], argvals = argvals,
lamvec = lambda, constr = constr, maxlam = maxlam)
################### <\MODIFICATION> ###################
cv = if (is . null(lambda))
lofo $objective
else min(lofo [, 2])
lambda = if (is . null(lambda))
lofo $min
else lofo [which.min(lofo[, 2]) , 1]
}
}
## FIRSTFIT (ADDITIVE MODEL WITH CONSTRAINTS)
## INITIAL COEFMAT
################### <MODIFICATION> ###################
firstfit

<− new.amc(as.vector(t(respmat)), X.sc %x% Bmat, gam.method = gam.method,
S = pen, C = constr, lambda = lambda)

################### <\MODIFICATION> ###################
coefmat = coefmat.ols = t(matrix( firstfit $coef, ncol = q))
se = NULL
## NON−OLS METHOD
if (method != ”OLS”) {
iter = 0
coefmat.old = 3 * coefmat.ols
newfit = NULL
if ( !is . null(lambda) & max.iter > 0)
warning(”Given lambda used for initial fit only”)
## CONVERGENCE CRITERION
while (any(abs((coefmat − coefmat.old)/coefmat.old) > 0.001) & (iter < max.iter)) {
iter = iter + 1
if (max.iter > 1)
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cat(” Refit ” , iter , ”\n”)
## SET LAST ESTIMATES AS OLD
oldfit = if ( !is . null( newfit ) )
newfit
else firstfit
coefmat.old = coefmat
## RESIDUAL VECTOR
residvec <− as.vector(t(respmat)) − (X.sc %x% Bmat) %*%
oldfit $coef[1:(q * nbasis)]
residmat = t (matrix(residvec, ncol = ncurve))
if (method == ”GLS”) {
if (cov.method == ”mod.chol”) {
p = ncol(residmat)
res.cent = scale(residmat, TRUE, FALSE)
sqrt.prec. list = list ()
lwstat = lwpval = c()
for (nband in 1:(p − 1)) {
TT = diag(p)
Ddiag = rep(0, p)
Ddiag[1] = var(res.cent [, 1])
for (k in 2:p) {
qrResCent <− qr(res.cent[, max(1, k − nband):(k − 1)])
TT[k, max(1, k − nband):(k − 1)] <− (−qr.coef(qrResCent, res.cent[, k]))
Ddiag[k] <− var(qr.resid(qrResCent, res.cent[, k]))
}
prec = scale(t(TT), FALSE, Ddiag) %*% TT
sqrt.prec. list [[ nband]] = scale(t(TT), FALSE, sqrt(Ddiag))
lwprec = lw. test (residmat %*% sqrt.prec.list[[nband]])
lwstat [nband] = lwprec$stat
lwpval[nband] = lwprec$pvalue
if ( lwstat [nband] < −5)
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break
if (nband > 5) {
if ( lwstat [nband] > lwstat[1] && lwstat[nband] >
lwstat [nband − 1])
break
}
}
nband.best = which.max(lwpval)
cat(”Using half−bandwidth”, nband.best, ”for precision matrix of residuals\n”)
sqrt.prec <− sqrt.prec.list [[ nband.best]]
}
else if (cov.method == ”naive”) {
if (nrow(residmat) < ncol(residmat))
stop(”Sample covariance matrix of residuals is singular.”)
svd.cov.mle <− svd(cov(residmat) * (ncurve − 1)/ncurve)
sqrt.prec <− tcrossprod(scale(svd.cov.mle$u,
FALSE, sqrt(svd.cov.mle$d)), svd.cov.mle$u)
}
newfit <− amc(as.vector(tcrossprod(sqrt.prec,respmat)),
X.sc %x% (sqrt.prec %*% Bmat), gam.method = gam.method,
S = pen, C = constr, start = if (is . null(con))
as.vector(t(coefmat))
else NULL)
coefmat = t(matrix(newfit$coef, ncol = q))
}
else if (method == ”mix”) {
if (resp.type == ”fd” ) {
resid.fd <− fd(solve(J12, t(residmat)), bss)
if ( iter == 1) {
pca.resid <− pca.fd(resid.fd, nharm = min(ncurve − 1, nbasis))
npc <− min(which(cumsum(pca.resid$varprop) > pve))
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}
else pca.resid <− pca.fd(resid.fd, nharm = npc)
evalues <− pca.resid$values[1:npc]
efuncmat.scaled <− Bmat %*% t(t(pca.resid$harmonics$coef[,1:npc]) * sqrt(evalues))
}
else if (resp.type == ”raw”) {
if ( iter == 1) {
pca.resid <− fpca.sc(residmat, pve = pve)
npc <− pca.resid$npc
}
else pca.resid <− fpca.sc(residmat, npc = npc)
evalues <− pca.resid$evalues
efuncmat.scaled <− t(t(pca.resid$efunctions) * sqrt(evalues))
}
if ( iter == 1)
cat(”Using leading”, npc, ”PCs of residual functions for random effects\n”)
npen <− length(pen)
pendim <− ncol(pen[[1]])
pen.aug = vector(” list ” , npen + 1)
for ( l in 1:npen) {
pen.aug[[l ]] <− matrix(0, pendim + npc * ncurve, pendim + npc * ncurve)
pen.aug[[l ]][1: pendim, 1:pendim] <− pen[[l]]
}
if ( iter == 1)
cat(”Using leading”, npc, ”PCs of residual functions for random effects\n”)
npen <− length(pen)
pendim <− ncol(pen[[1]])
pen.aug = vector(” list ” , npen + 1)
for ( l in 1:npen) {
pen.aug[[l ]] <− matrix(0, pendim + npc * ncurve, pendim + npc * ncurve)
pen.aug[[l ]][1: pendim, 1:pendim] <− pen[[l]]

57

}
pen.aug[[npen + 1]] <− diag(rep(0:1, c(pendim, npc * ncurve)))
constr.aug <− if (is. null(constr) )
NULL
else cbind(constr, matrix(0, nrow(constr), npc * ncurve))
startB <− if ( iter == 1) {
c(as.vector(t(coefmat)), rep(0, ncurve * npc))
}
else {
newfit$coefficients
}
newfit <− amc(as.vector(t(respmat)),
cbind(X.sc %x% Bmat, diag(ncurve) %x% efuncmat.scaled),
gam.method = gam.method, S = pen.aug, C = constr.aug,
start = if (is . null(constr.aug)) startB
else NULL)
vecBt = newfit$coef[1:(q * nbasis)]
vecUt = newfit$coef[(q * nbasis + 1) :( q * nbasis + npc * ncurve)]
coefmat = t(matrix(vecBt, ncol = q))
U <− t(matrix(vecUt, ncol = ncurve))
}
}
}
## OLS METHOD
if (method == ”OLS” | max.iter == 0) {
residvec <− as.vector(t(respmat)) − (X.sc %x% Bmat) %*% firstfit$coef
covmat = ((ncurve − 1)/ncurve) * cov(t(matrix(residvec, ncol = ncurve)))
var.b = firstfit $GinvXT %*% (diag(ncurve) %x% covmat) %*% t(firstfit$GinvXT)
}
else var.b = newfit$Vp
## STANDARD ERRORS
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se.func = matrix(NA, length(argvals), q)
################### <MODIFICATION> ###################
for ( j in 1:q) {
se.func [, j ] = sqrt(rowSums((Theta %*%
var.b [(( nbasis−2*excl.basis) * ( j − 1) + 1) :(( nbasis−2*excl.basis) * j ) ,
(( nbasis−2*excl.basis) * ( j − 1) + 1) :(( nbasis−2*excl.basis) * j ) ]) *
Theta))
}
for( i in 1:excl .basis) {
coefmat <− cbind(0,coefmat,0)
}
################### <\MODIFICATION> ###################
fd = fd( t (coefmat), bss)
est.func = eval.fd(argvals, fd)
fit <− if (method == ”mix” & max.iter > 0)
newfit
else firstfit
roughness = diag(coefmat %*% getbasispenalty(bss, pen.order) %*% t(coefmat))
skale = attr (X.sc, ”scaled:scale”)
if ( !is . null(skale)) {
coefmat = t(scale(t(coefmat), center = FALSE, scale = skale))
est.func = scale(est.func, center = FALSE, scale = skale)
se.func = scale(se.func, center = FALSE, scale = skale)
roughness = roughness/skaleˆ2
}
yhat = if (resp.type == ”raw”)
X %*% tcrossprod(coefmat, Theta)
else fd( t (X %*% coefmat), bss)
llist = list (fd = fd , pca.resid = pca.resid, U = U, yhat = yhat,
resid = if (resp.type == ”raw”) Y − yhat else fdobj − yhat,
est.func = est.func, se.func = se.func, argvals = argvals,
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fit = fit , edf = sum(fit$gam$edf),
lambda = if (length( fit $gam$sp) > 0)
fit $gam$sp
else fit $gam$full.sp, cv = cv, roughness = roughness,
resp.type = resp.type)
class( llist ) = ” fosr ”
llist
}

# Leave−one out cross−validation function for rfosr
# from fosr internal function lofocv (Reiss et al . 2010)
new.lofocv <− function(Y, X, S1, argvals, lamvec=NULL, constr=NULL, maxlam=NULL) {
nn = nrow(X)
N = NROW(Y); K = NCOL(Y)
if (N*K!=nn) stop(’Number of elements of Y must equal number of rows of X’)
y = as.vector(t(Y))
if ( !is . null(constr) ) {
# The following is based on Wood (2006), p. 186
n.con = dim(constr)[1]
Z. = qr.Q(qr(t(constr) ) , complete=TRUE)[ , −(1:n.con)]
X. = X %*% Z.
S1. = crossprod(Z., S1 %*% Z.)
}
else {
X. = X
S1. = S1
}
qrX = qr(X.)
Rinv = solve(qr.R(qrX))
svd211 = svd(crossprod(Rinv, S1. %*% Rinv)) # see p. 211 of Wood
QU = qr.Q(qrX) %*% svd211$u
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# calculate the weight for the approx. integral using argvals
vecWeight = diff(argvals, 2)/2
vecWeight = c((argvals[2]−argvals[1])/2, vecWeight, (argvals[N]−argvals[N−1])/2)
cvfcn = function(lam) {
A = tcrossprod(scale(QU, center=FALSE, scale=1+lam*svd211$d), QU)
resmat = t(matrix(y − A %*% y, K))
MSEp = 0
for ( i in 1:N) {
ith = (( i −1)*K+1):(i*K)
# when no argvals is used
# MSEp = MSEp + crossprod(solve(diag(K)−A[ith,ith], resmat[i, ])) / N
# when new argvals is implemented
MSEp = MSEp + crossprod(solve(diag(K)−A[ith,ith], resmat[i, ])) * vecWeight[i]
}
MSEp
}
if (is . null(lamvec)) { # minimize LOFO−CV criterion
if (is . null(maxlam)) { # use GCV−minimizing lambda
model.gcv = gam(y˜X.−1, paraPen=list(X.=list(S1.)), method=”GCV.Cp”)
maxlam = model.gcv$sp
}
cat(”Finding optimal lambda by optimize()...\n”)
opt = optimize(cvfcn, c(0, maxlam), tol=.01)
if (round(opt$minimum)==maxlam) warning(”maxlam may be set too low”)
return(opt)
}
else { # calculate LOFO−CV for given values
cvvals = c()
cat(”Calculating CV for candidate smoothing parameter values...\n”)
for ( i in 1:length(lamvec)) cvvals[i ] = cvfcn(lamvec[i ])
cvtable = cbind(lamvec, cvvals)
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dimnames(cvtable)[[2]] = c(’lambda’, ’LOFO−CV’)
print(cvtable)
return(cvtable)
if (which.min(cvvals)==1) warning(”CV minimized at lowest lambda considered”)
if (which.min(cvvals)==length(lamvec)) warning(”CV minimized at highest lambda
considered”)
}
}

# Internal function for additive models with constraints used in rfosr
# from fosr internal function amc (Reiss et al . 2010)
new.amc <− function(y, Xmat, S, gam.method=’REML’, C=NULL, lambda=NULL, ...) {
n.p = length(S)
if ( !is . null(C)) {
# The following is based on Wood (2006), p. 186
n.con = dim(C)[1]
Z. = qr.Q(qr(t(C)), complete=TRUE)[ , −(1:n.con)]
Xmat. = Xmat %*% Z.
S. = vector(” list ” , n.p)
for ( i in 1:n.p) S .[[ i ]] = crossprod(Z., S[[i ]] %*% Z.)
}
else {
Z. = diag(ncol(Xmat))
Xmat. = Xmat
S. = S
}
fitter = if (length(y) > 10000) bam else gam
if (is . null(lambda)) fitobj = fitter (y ˜ Xmat.−1, method=gam.method, paraPen=list(Xmat.=
S.), ...)
else fitobj = fitter (y ˜ Xmat.−1, paraPen=list(Xmat.=S.), sp=lambda, ...)
lambdavec = if (!is . null( fitobj $ full .sp)) fitobj $ full .sp else fitobj $sp

62

fullpen = 0
for ( i in 1:n.p) fullpen = lambdavec[i] * S .[[ i ]]
list (gam = fitobj ,
coefficients = Z. %*% fitobj$coef,
Vp = Z. %*% fitobj$Vp %*% t(Z.),
GinvXT = Z. %*% solve(crossprod(Xmat.) + fullpen, t(Xmat.)),
method = gam.method)
}
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APPENDIX C
BUGS

CODE FOR NONLINEAR MIXED EFFECTS MODELING

C.1. Specification for Simulation 1a
model {
# Priors for global parameters
sigma˜dunif(0, 100) # Residual standard deviation
tau <− 1/(sigma*sigma)
# Hyperpriors for subject−specific parameters
p˜dbeta(1,1)
for ( i in 1:ngroups) {
A[i ] ˜dunif(0.65,0.75)
group[i ] ˜dbern(p)
m1[i] ˜dunif(50,90)
m2[i] ˜dnorm(500,1/sqrt(10))
M[i]<−m1[i]*group[i]+m2[i]*(1−group[i])
}
# Likelihood
for ( i in 1:n) {
# Expectation
mu[i] <− A[id[i ]] + (1.2−A[id[ i ]]) /(1 + exp(−0.15*(x[i]−M[id[i ]]) ) )
# Actual response
y[ i ] ˜ dnorm(mu[i], tau)
}
}

C.2. Specification for Simulation 2a
model {
# Priors for global parameters
sigma˜dunif(0, 100) # Residual standard deviation
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tau <− 1/(sigma*sigma)
# Hyperpriors for subject−specific parameters
beta0 ˜ dnorm(0,1)
beta1 ˜ dnorm(0,1)
M1 ˜ dnorm(75,0.01)
delta ˜ dnorm(0,0.01)
for ( i in 1:ngroups) {
logit (p[ i ]) <− beta0 + beta1*cat[i]
A[i ] ˜dunif(0.65,0.75)
group[i ] ˜dbern(p[i ])
m1[i] ˜dnorm(M1*cat[i] + (M1+delta)*(1−cat[i]),0.01)
m2[i] ˜dnorm(500,1/sqrt(10))
M[i]<−m1[i]*group[i]+m2[i]*(1−group[i])
}
# Likelihood
for ( i in 1:n) {
# Expectation
mu[i] <− A[id[i ]] + (1.2−A[id[ i ]]) /(1 + exp(−0.15*(x[i]−M[id[i ]]) ) )
# Actual response
y[ i ] ˜ dnorm(mu[i], tau)
}
}

C.3. Specification for ADNI data
model {
# Priors for global parameters
sigma˜dunif(0, 100) # Residual standard deviation
tau <− 1/(sigma*sigma)
sigma M1˜dunif(0, 100) # M1 standard deviation
tau M1 <− 1/(sigma M1*sigma M1)
# Hyperpriors for subject−specific parameters
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beta0 ˜ dnorm(0.5,1)
beta1 ˜ dnorm(0,1)
M1 ˜ dnorm(75,0.01)
delta ˜ dnorm(0,0.01)
for ( i in 1:ngroups) {
logit (p[ i ]) <− beta0 + beta1*apoe[i]
A[i ] ˜dunif(0.6,0.8)
group[i ] ˜dbern(p[i ])
m1[i] ˜dnorm(M1+delta*apoe[i],tau M1)
m2[i] ˜dnorm(500,1/sqrt(10))
M[i]<−m1[i]*group[i]+m2[i]*(1−group[i])
}
# Likelihood
for ( i in 1:n) {
# Expectation
mu[i] <− A[id[i ]] + (1.1−A[id[ i ]]) /(1 + exp(−0.15*(x[i]−M[id[i ]]) ) )
# Actual response
y[ i ] ˜ dnorm(mu[i], tau)
}
}
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